Quadrosilan

• Identification
• Experimental evidence
• Physicochemical properties
• ADMET properties
• Chemical-gene interaction
• Descriptors
• Presence in chemical regulation or guideline
• Presence in human biospecimen

Literature identifier	Study type	Test dosage	Effective dosage	Endocrine-mediated endpoints	Systems-level perturbations
PMID:1080335	IVR	33 mg/kg	33 mg/kg	Decreased testosterone levels	Reproductive endocrine-mediated perturbations
	IVR	33 mg/kg	33 mg/kg	Decreased weights of seminal vesicles	Reproductive endocrine-mediated perturbations
	IVR	33 mg/kg	33 mg/kg	Decreased FSH levels	Reproductive endocrine-mediated perturbations
	IVR	33 mg/kg	33 mg/kg	Decreased prostate weights	Reproductive endocrine-mediated perturbations
	IVR	33 mg/kg	33 mg/kg	Affects sexual behavior	Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations
	IVR	33 mg/kg	33 mg/kg	Decreased LH levels	Reproductive endocrine-mediated perturbations
PMID:1080337	IVR	0.001 - 33.3 mg/kg/day	3 mg/kg/day	Affects fertility	Reproductive endocrine-mediated perturbations
	IVR	0.001 - 33.3 mg/kg/day	0.33 mg/kg/day	Affects fertility	Reproductive endocrine-mediated perturbations
PMID:4651163	IVR	0.01 - 33.3 mg/kg/day	0.33 mg/kg/day	Affects fertility	Reproductive endocrine-mediated perturbations
PMID:496515	IVR	40 mg/kg/day	40 mg/kg/day	Affects cholesterol metabolism	Metabolic endocrine-mediated perturbations
	IVR	40 mg/kg/day	40 mg/kg/day	Changes in morphology of pituitary gland	Neurological endocrine-mediated perturbations
	IVR	40 mg/kg/day	40 mg/kg/day	Changes in morphology of accessory sex organs	Reproductive endocrine-mediated perturbations
	IVR	20 mg/kg/day	20 mg/kg/day	Affects cholesterol metabolism	Metabolic endocrine-mediated perturbations
	IVR	20 mg/kg/day	20 mg/kg/day	Changes in morphology of pituitary gland	Neurological endocrine-mediated perturbations
	IVR	20 mg/kg/day	20 mg/kg/day	Changes in morphology of accessory sex organs	Reproductive endocrine-mediated perturbations

---

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.